Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
37 hedge funds and large institutions have $305M invested in Verona Pharma in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
28% more capital invested
Capital invested by funds: $238M → $305M (+$66.9M)
6% more funds holding
Funds holding: 35 → 37 (+2)
0.32% less ownership
Funds ownership: 8.62% → 8.3% (-0.32%)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $100K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.2M |
| 2 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$9.22M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$1.07M |
| 4 |
QSS
Quantitative Systematic Strategies
Ponte Vedra Beach,
Florida
|
+$242K |
| 5 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$14.7M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$5.19M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.93M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.25M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.19M |
VRNA Hedge Fund Activity: Q1 2021 in Review
37 of the 5,699 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q1 2021, worth a combined $305M — up 28% from $238M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VRNA positions and 5 closed out — a net gain of 2 holders — while 7 added to existing stakes and 10 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $21.2M. The largest seller was Novo Holdings A/S, cutting an estimated $14.7M.
- 37 institutional investors held Verona Pharma (VRNA) as of Q1 2021, up from 35 in Q4 2020.
- Funds reported $305M of Verona Pharma stock for Q1 2021, up 28% quarter-over-quarter.
- 7 funds opened new Verona Pharma positions in Q1 2021 and 5 closed out, a net change of +2 holders.
- The largest Verona Pharma buyer in Q1 2021 was Wellington Management Group, an estimated $21.2M added.
- The largest Verona Pharma seller in Q1 2021 was Novo Holdings A/S, an estimated $14.7M sold.
Based on aggregated 13F filings for Q1 2021.